Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
schoolROCK pediatric cGVHD study of belumosudil
CTR20254242Phase 2Active
- Sponsor
- Sanofi
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Sanofi. Started Jan 2026; status: active.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on CTR20254242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254242.